1. (Original) A compound having the structure of Formula I



Formula I

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides

wherein

m is an integer from 0-2;

R_1 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl, or heterocyclylalkyl;

R_2 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

R_1 and **R_2** may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, aryloxy, halogen (F,Cl, Br, I), aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl;

R_3 can be NH_2, NHOH, NHOR (wherein R can be alkyl, alkenyl, alkynyl, cycloalkyl or aralkyl), or OR_m (wherein R_m can be hydrogen, alkyl, aralkyl, aryl, or metal ions (Na^+, K^+, Li^+, Ca^+ or Mg^+));

R_4 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, $-(CH_2)_{1-4}$-O-R′ (wherein R′ can be selected from the group

consisting of hydrogen, alkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclylalkyl, or heteroarylalkyl), –C(=O)-R_3 (wherein R_3 is the same as defined above) –C(=O)R_Z (wherein R_z is –NR_7R_8 wherein R_7 and R_8 can be independently selected from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO_2R_9 (wherein R_9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or **R_7** and **R_8** may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, -YR_u (wherein Y is C(=O), C(=S) or SO_2 and R_u is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), -C(=T)NR_u (wherein T is oxygen, sulphur, -$CH(NO_2)$, -$N(NO_2)$ or -N(CN) and R_u is the same as defined above) or -C(=O)OR_u (wherein R_u is the same as defined above)];

R_5 and **R_6** may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or **R_5** and **R_6** may together join to form a cycloalkyl ring.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Original) A compound according to claim 1, wherein R_2 is optionally substituted aralkyl.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Original) A compound according to claim 1, wherein R_2 is heteroarylalkyl.

17. (Cancelled)

18. (Original) A compound according to claim 1, wherein R_2 is aryl.

19. (Cancelled)

20. (Original) A compound according to claim 1, wherein R_1 and R_2 may also together join to form cyclic ring (3-8 membered), optionally benzofused containing 0-4 heteroatoms O, S or N.

21. (Cancelled)

22. (Original) A compound according to claim 1, wherein R_3 is –ORm or $–NH_2$.

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Original) A compound according to claim 22, wherein R_3 is $-NH_2$.

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

43. (Cancelled)

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Cancelled)

49. (Cancelled)

50. (Cancelled)

51. (Cancelled)

52. (Cancelled)

53. (Cancelled)

54. (Cancelled)

55. (Cancelled)

56. (Cancelled)

57. (Cancelled)

58. (Cancelled)

59. (Original) A compound of claim 1, wherein R_4 is $-C(=O)R_3$.

60. (Cancelled)

61. (Cancelled)

62. (Cancelled)

63. (Cancelled)

64. (Cancelled)

65. (Original) A compound of claim 1, wherein R_5 is hydrogen, alkyl or aryl.

66. (Cancelled)

67. (Cancelled)

68. (Cancelled)

69. (Cancelled)

70. (Cancelled)

71. A compound of claim 1, wherein R_6 is hydrogen.

72. (Cancelled)

73. (Cancelled)

74. (Cancelled)

75. (Cancelled)

76. (Cancelled)

77. (Original) A compound selected from

(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxy-phenyl)-propionic acid (Compound No. 1),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 2),

(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 3),

(S)-3-(4-Hydroxy-phenyl)-2-{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 4),

(S)-2-{[(4R,5R)-5-(2-Methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 5),

(S)-3-[4-(2,6-difluoro-benzyloxy)phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound no. 6),

(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 7),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 8),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 9),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No.10),

Lithium salt of (S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No.11),

Lithium salt of (S)-2-{[(4R,5R)-5-(2-Methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No. 12),

Lithium salt of (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxalane-4-carbonyl]-amino}-3-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-propionate (Compound No. 13),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 14),

Morpholine-4-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenyl ester (Compound No. 15),

4-Methyl-piperazine-1-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenylester (Compound No. 16),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 17),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(2,6-dichloro-pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 18),

(S)-2-{[(4R,5R)-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(piperidine-4-carbonyl)-amino]-phenyl}-propionic-acid, salt with trifluoroacetic acid (Compound No.19),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridine-3-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 20),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridine-2-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 21),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[6-bromo-pyridine-2-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 22),

(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 23),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxyl-phenyl)-propionic acid (Compound No. 24),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 25),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-chloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 26),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-prop-2-ynyloxy-phenyl)-propionic-acid (Compound No. 27),

(S)-3-{4-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-phenyl}-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 28),

(S)-2-{[(4R,5R)-5-(Biphenyl-2-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-methoxy-benzyl-amino)-phenyl]–propionic acid (Compound No 29),

(S)-2-{(4R,5R)-5-(3,5-Dichlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy]-phenyl]-propionic-acid (Compound No. 30),

(S)-3-(4-(2,6-Dichlorobenzyloxy)-phenyl]-2-[{(4R,5R)-5-[thiophen-2-yl-methyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 31),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-phenyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (compound no 32),

(S)-2-{[(4S,5S)-5-(2-Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-[(pyridin-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No 33),

(S)-2-{[(4S,5S)-5-(Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichlorobenzloxy-phenyl]-propionic acid (Compound No.34),

(4R,5R)-5-{(S)-1-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl}-[1,3]dioxolane-4-carboxylic acid (Compound No. 35),

Lithium salt of (S)-2-[{(4R,5R)-5-Cyclopropyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichlorobenzyloxy)-phenyl]-propionate (Compound No. 36),

(S)-2-[{(4R,5R)-5-Cyclohexane-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No 37) ,

(S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{([4R,5R)-5-(thiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 38) ,

(S)-2-{[(4R,5R)-5-(Cyclopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl)-amino]-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No 39) ,

(S)-2-[{(4R,5R)-5-Cyclohexyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 40),

(S)-2-{[4R,5R)-5-(3,5-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbamoyl]-amino}-3-{4-[(pyridine-4-carbonyl-amino]-phenyl}-propionic acid (Compound No. 41) ,

(4R,5R)-5-[(S)-1-Carboxy-2-[4-(hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 42) ,

(S)-3-(4-benzoylaminophenyl)-2-[{(4R,5R)-5-(isopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 43),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl-2-{[(4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid salt with trifluoroacetic acid (Compound No 44),

(S)-2-{[(4R,5R)-5-(2,6-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 45),

(4R,5R)-5-{(S)-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethylcarbamoyl]-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-isopropylcarbamoyl-[1,3]dioxolane-4-carbonyl}-amino]- propionic acid (Compound No.47),

(S)-2-[{(4R,5R)-5-tert-Butyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 48),

(S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-[{(4R,5R)-5-(3-methyl-butylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 49),

(S)-3-[4-(2,6,Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(R)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 50),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(S)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 51),

(S)-1-{(4R,5R)-5-{(S)-1-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl}-[1,3]dioxolane-4-carbonyl}-pyrolidine-2-carboxylic acid benzyl ester(Compound No. 52),

(S)-2-{[(4R,5R)-5-(Benzothiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.53),

(S)-2-[(4R,5R)-{5-Benzyloxy-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 54),

(S)-3-[4-2-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholine-4-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No.55),

(S)-2-[((4R,5R)-{5-allyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 56),

1-{(4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-pyrolidine–2-carboxylic acid (Compound No.57),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(tetrahydro-furan-2-yl-methyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 58),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[2-(1H-indol-3-yl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 59),

(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(2-thiophen-2-yl-ethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 60),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-[(pyridin-4-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.61),

(S)-3-[4-(2,6,-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,3-dihydro-indole-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 62),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-methyl-[1,3,4]thiadiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No.63),

(S)-2{[(4R,5R)-5-(Biphenyl–2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxyphenyl)-propionic acid (Compound No. 64),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-(methyl-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.65),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl)-2-[{4R,5R)-5-[methyl-(1-methyl-piperidine-4-yl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 66),

(S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-{[(4R,5R)-5-(2-fluoro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 67),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 68),

(S)-2-{[(4R,5R)-5-(4-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.69),

(S)-2-{[(4R,5R)-5-(3-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 70),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,5-dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic-acid (Compound No.71),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[4R,5R)-5-(2,6-dichlorophenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 72),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-O-tolyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound no.73),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-dimethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 74),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl)-2-[{(4R,5R)-5-methyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]- propionic acid (Compound No.75),

(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-methoxy-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 76),

(4R,5R)-5-{(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichlorobenzyloxy-phenyl]-ethylcarbamoyl]-[1,3]dioxolane-4-carboxylic acid (Compound No.77),

(S)-2,3-[4(2,6-Dichloro-benzyloxy)-phenyl]–2-[{(4R,5R)-5-[2-(4-hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 78),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyrrolidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 79),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(R)-3-hydroxy-pyrrolidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 80),

1-((4R,5R)-5-{(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethylcarbamoyl}-[1,3]dioxolane-4-carbonyl)-pyrrolidine-2-carboxylic acid (Compound No. 81),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(1-hydroxymethyl-propylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 82),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-ethylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 83),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-prop-2-ynylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 84),

Trifluoroacetate salt of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-morpholin-4-yl-ethylcarbamoyl)-[1,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 85),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(piperidin-1-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 86),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 87),

(S)-2-{[4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88),

(S)-2-{[(4R,5R)-5-(Bicyclo[2.2.1]hept-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 89),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 90)

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 91),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 92),

(S)-2-{[(4R,5R)-5-(2,6-Difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino}-3-(4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 93),

(S)-2-{[(4R,5R)-5-(2,6-Diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 94),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-hydroxymethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 95),

(S)-2-[((4R,5R)-5-Carbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 96),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-((R)-2-hydrox-1-phenyl-ethylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 97),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-phenyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 98,)

(S)-2-{[(4R,5R)-5-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 99),

(S)-2-{[(4R,5R)-5-(2-sec-Butyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 100),

(S)-2-[((4R,5R)-5-Benzyloxymethyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 101),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-trifluoromethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 102),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropoxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 103),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid Compound No. 104),

(S)-2-{[(4R,5R)-5-Cyclopentylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 105),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-hexylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 106),

(S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,4-dimethyl-isoxazol-5-ylcarbamoyl)-[1,3]-dioxolane-4-carbonyl]amino-propionic acid (Compound No. 107),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyridin-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 108),

{2-[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolone-4-carbonyl]-1,2,3,4-tetrahydro-isoqunoline}-3-carboxylic acid (Compound No. 109),

2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(1H-indol-3-yl)-propionic acid (Compound No. 110),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 111),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 112),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-methyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 113),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-cyclohexylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 114),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 115),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-heptylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 116),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-ethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 117),

(4R,5R)-[1,3]Dioxolane-4,5-dicarboxylic acid-4-({(S)-1-carbamoyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl}-amide)-5-[(2-chloro-phenyl)-amide] (Compound No. 118),

(S)-2-{[(4R,5R)-5-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 119),

(S)-2-[((4R,5R)-5-cycloheptylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 120),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-ethylsulphanyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 121),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((S)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 122),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4,5-dimethylthiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 123),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((R)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 124),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-oxo-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 125),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl)-methyl-amino]-propionic acid (Compound No. 126),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(indan-5-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 127),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{((4R,5R)-5-phenethylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 128),

(S)-2-({(4R,5R)-5-[(Benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 129),

(S)-2-{[(4R,5R)-5-Butylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 130),

(S)-2-{[(4R,5R)-5-(4-Acetyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzylxoy)-phenyl]-propionic acid (Compound No. 131),

(S)-2-{[(4R,5R)-5-(2-Cyclopentyloxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzylxoy)-phenyl]-propionic acid (Compound No. 132),

(S)-2-{[(4R,5R)-5-(2-Cyclopentyloxy-5-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 133),

3-Benzo[1,3]dioxol-5-yl-3-{[(4R,5R)-5-(2-chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 134),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(2-methoxy-biphenyl-4-yl)-propionic acid (Compound No. 135),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-fluoro-phenyl)-propionic acid (Compound No. 136),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(2,6-dimethoxy-biphenyl-4-yl)-propionic acid (Compound No. 137),

(S)-3-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 138),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-octylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 139),

3-[((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-(3,4-dimethoxy-benzyl)-amino]-propionic acid (Compound No. 140),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 141),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-(3,5-dichloro-pyridin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 142),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-[((4R,5R)-5-(2-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 143),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-({(4R,5R)-5-[2-(1H-indol-3-yl)-ethylcarbamoyl]-[1,3]dioxolane-4-carbonyl}-amino)-propionic acid (Compound No. 144),

(S)-2-[((4R,5R)-5-Cyclohexylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 145),

Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezyloxy)-phenyl]-2-[((4R,5S)-5-pyrrolidin-1-ylmethyl-[1,3]Dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 146),

(S)-2-[((4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 147),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-({(4R,5R)-5-[(thiophen-2-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino)-propionic acid (Compound No. 148),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-2,2,5-trimethyl-[1,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 149),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(thiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 150),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 151),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 152),

(S)-2-{[(4R,5R)-5-Cyclopropylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 153), and

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(piperidin-1-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 154).

78. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 together with pharmaceutically acceptable carrier, excipients or diluents.

79. (Original) A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable excipient.

80. (Original) A method of preventing, inhibiting or suppressing inflammatory condition in an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1.

81. (Original) A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 79.

82. (Original) A method of preventing, inhibiting or suppressing inflammatory disease in an animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 78.

83. (Currently Amended) A method of preparing a compound of Formula XVI



Formula XVI

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;



Formula II



Formula III

condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;



Formula IV



Formula V

hydrolyzing the compound of Formula V to yield a compound of Formula VI;



Formula VI

condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);



Formula VII



Formula VIII

reducing the compound of Formula VIII to yield a compound of Formula XIII

(when R_2 is 

);



Formula XIII

reacting the compound of Formula XIII with a compound of Formula XIV to yield a compound of Formula XV; and



Formula XIV



Formula XV

hydrolyzing the compound of Formula XIV to yield a compound of Formula XVI,



Formula XVI

wherein

wherein R_7 and R_8 are independently selected from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, $SO_2R_{9'}$ (wherein $R_{9'}$ can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or $\mathbf{R_7}$ and $\mathbf{R_8}$ may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, $-YR_u$ (wherein Y is C(=O), C(=S) or SO_2 and R_u is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), $-C(=T)NR_u$ (wherein T is oxygen, sulphur, $-CH(NO_2)$, $-N(NO_2)$ or -N(CN) and R_u is the same as defined above) or $-C(=O)OR_u$ (wherein R_u is the same as defined above)];

$\mathbf{R_5}$ and $\mathbf{R_6}$ are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or $\mathbf{R_5}$ and $\mathbf{R_6}$ may together join to form a cycloalkyl ring; and

R_9 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl.

84. (Cancelled)

85. (Currently Amended) A method of preparing a compound of Formula XII



Formula XII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises:

hydrolyzing a compound of Formula II to yield a compound of Formula III;



Formula II



Formula III

condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;



Formula IV



Formula V

hydrolyzing the compound of Formula V to yield a compound of Formula VI;



Formula VI

condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl); and



Formula VII



Formula VIII

hydrolyzing the compound of Formula VIII ~~is hydrolyzed~~ to yield a compound of Formula XII~~,~~



Formula XII

wherein

wherein R_7 and R_8 are independently selected from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO_2R_9 (wherein R_9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or R_7 and R_8 may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino,

substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, $-YR_u$ (wherein Y is C(=O), C(=S) or SO_2 and R_u is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), $-C(=T)NR_u$ (wherein T is oxygen, sulphur, $-CH(NO_2)$, $-N(NO_2)$ or -N(CN) and R_u is the same as defined above) or $-C(=O)OR_u$ (wherein R_u is the same as defined above)]; and

R_5 and **R_6** are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or **R_5** and **R_6** may together join to form a cycloalkyl ring.

86. (Cancelled)

87. (Currently Amended) A method for preparing a compound of Formula XXI



Formula XXI

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;



Formula III



Formula XVII



Formula XVIII

hydrolyzing the compound of Formula XVIII to yield a compound of Formula XXII; and



Formula XXII

condensing the compound of Formula XXIII with a compound of Formula IV to yield a compound of Formula XXI,



Formula XXI

wherein

R_2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

R_7 and R_8 are independently selected from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO_2R_9 (wherein R_9 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or R_7 and R_8 may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, $-YR_u$ (wherein Y is C(=O), C(=S) or SO_2 and R_u

is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), $-C(=T)NR_u$ (wherein T is oxygen, sulphur, $-CH(NO_2)$, $-N(NO_2)$ or -N(CN) and R_u is the same as defined above) or $-C(=O)OR_u$ (wherein R_u is the same as defined above)];

$\mathbf{R_5}$ and $\mathbf{R_6}$ are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or $\mathbf{R_5}$ and $\mathbf{R_6}$ may together join to form a cycloalkyl ring; and

wherein P is methyl, ethyl t-butyl or benzyl.

88. (Cancelled)

89. (Currently Amended) A method for preparation of compound of Formula XXVII



Formula XXVII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

reducing the compound of Formula XXV



Formula XXV

to yield a compound of Formula XXVI (wherein P_1 is ethyl, t-butyl, or benzyl); and



Formula XXVI

hydrolyzing the compound of Formula XXVI to furnish a compound of Formula XXVII,



Formula XXVII

wherein

R_2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; and

R_5 and R_6 are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R_5 and R_6 may together join to form a cycloalkyl ring.

90. (Currently Amended) A method for preparation of compound of Formula XXIII



Formula XXXIII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

reducing the compound of Formula XXV



Formula XXV

to yield a compound of Formula XXVI (wherein P_1 is ethyl, t-butyl, or benzyl); ~~and~~

reacting the compound of Formula XXVI with a compound of Formula Rm-hal to yield a compound of Formula XXVIII; and



Formula XXVIII

hydrolyzing the compound of Formula XXVIII to yield a compound of Formula XXXIII,



Formula XXXIII

wherein

m is an integer from 0-2;

R_2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

R_5 and R_6 are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R_5 and R_6 may together join to form a cycloalkyl ring; and

R_m is hydrogen, alkyl, aralkyl, aryl, or metal ion.

91. (Cancelled)

92. (Currently Amended) A method for preparation of compound of Formula XXXII



Formula XXXII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

reducing the compound of Formula XXV



Formula XXV

to yield a compound of Formula XXVI (wherein P_1 is ethyl, t-butyl, or benzyl); ~~and~~

reacting the compound of Formula XXVI with a compound of Formula L-hal to yield a compound of Formula XXX;



Formula XXX

condensing the compound of Formula XXX with a compound of Formula IV (wherein OL is a leaving group selected from, mesyl or tosyl) to yield a compound of Formula XXXI; and



Formula IV



Formula XXXI

hydrolyzing the compound of Formula XXXI to yield a compound of Formula XXXII,



Formula XXXII

wherein

R_2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

$\mathbf{R_5}$ and $\mathbf{R_6}$ are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or $\mathbf{R_5}$ and $\mathbf{R_6}$ may together join to form a cycloalkyl ring; and

R_7 and R_8 are independently selected from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO_2R_9 (wherein R_9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or $\mathbf{R_7}$ and $\mathbf{R_8}$ may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, $-YR_u$ (wherein Y is C(=O), C(=S) or SO_2 and R_u is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), $-C(=T)NR_u$ (wherein T is oxygen, sulphur, $-CH(NO_2)$, $-N(NO_2)$ or -N(CN) and R_u is the same as defined above) or $-C(=O)OR_u$ (wherein R_u is the same as defined above)].

93. (Currently Amended) A method for the preparation of the compound of Formula XXXVIII



Formula XXXVIII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

hydrolyzing a compound of Formula XXXV to yield a compound of Formula XXXVI;



Formula XXXV



Formula XXXVI

reacting the compound of Formula XXXVI with a compound of Formula VII to yield a compound of Formula XXXVII; and



Formula VII



Formula XXXVII

hydrolyzing the compound of Formula XXXIII to yield a compound of Formula XXXVIII, wherein R_t is H or CH_3; P is methyl, ethyl, t-butyl or benzyl; R_2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; and $\mathbf{R_5}$ and $\mathbf{R_6}$ are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or $\mathbf{R_5}$ and $\mathbf{R_6}$ may together join to form a cycloalkyl ring;

R_7 and R_8 are independently selected from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO_2R_9 (wherein R_9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or $\mathbf{R_7}$ and $\mathbf{R_8}$ may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, $-YR_u$ (wherein Y is C(=O), C(=S) or SO_2 and R_u is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), $-C(=T)NR_u$ (wherein T is oxygen, sulphur, $-CH(NO_2)$, $-N(NO_2)$ or -N(CN) and R_u is the same as defined above) or $-C(=O)OR_u$ (wherein R_u is the same as defined above)].

94. (Currently Amended) A method for the preparation of the compound of Formula XL



Formula XL

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

condensing a compound of Formula VI with a compound of Formula XXXIX



Formula VI



Formula XXXIX

to yield a compound of Formula XL,

wherein

R_2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

R_7 and R_8 are independently selected from hydrogen (provided that both R_7 and R_8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO_2R_9 (wherein R_9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or **R_7** and **R_8** may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or $(CH_2)_{1-4}NR_xR_y$ [wherein R_x and R_y can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, $-YR_u$ (wherein Y is C(=O), C(=S) or SO_2 and R_u is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), $-C(=T)NR_u$ (wherein T is oxygen, sulphur, $-CH(NO_2)$, $-N(NO_2)$ or -N(CN) and R_u is the same as defined above) or $-C(=O)OR_u$ (wherein R_u is the same as defined above)]; and

R_5 and **R_6** are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or **R_5** and **R_6** may together join to form a cycloalkyl ring.

95. (Original) A compound of claim 1, wherein

R_1 is hydrogen;

R_2 is  ;

R_3 is –OH;

R_4 is $-C(=O)R_z$;

R_5 is hydrogen;

R_6 is hydrogen; and

m is 0, wherein W is H, OH, NHCO-$(CH_2)_{0-3}$-aryl, NHCO-$(CH_2)_{0-3}$-substituted aryl, NHCO-$(CH_2)_{0-3}$-heteroaryl, NHCO-$(CH_2)_{0-3}$-substituted aryl, OCO-$(CH_2)_{0-3}$-aryl, OCO-$(CH_2)_{0-3}$-substituted aryl, OCO-$(CH_2)_{0-3}$-heterosryl, OCO-$(CH_2)_{0-3}$-substituted aryl, O-$(CH_2)_{0-3}$-heterocyclyl, -O-$(CH_2)_{0-3}$-substituted heterocyclyl, NHCO-$(CH_2)_{0-3}$-heterocyclyl, NHCO-$(CH_2)_{0-3}$-substituted heterocyclyl, O-$(CH_2)_{0-3}$-alkynyl, O-$(CH_2)_{0-3}$-alkenyl, or halogen.

96. (Original) The compound of claim 95, wherein R_z is –NH-$(CH_2)_{0-3}$-aryl, -NH-$(CH_2)_{0-2}$-substituted aryl, -NH-$(CH_2)_{0-3}$-cycloalkyl, -NH-$(CH_2)_{0-3}$-heteroaryl, -NH-$(CH_2)_{0-3}$-heterocyclyl, -NH-$(CH_2)_{0-3}$-substituted cycloalkyl, -NH-$(CH_2)_{0-3}$-substituted heteroaryl, -NH-$(CH_2)_{0-3}$-substituted heterocyclyl, N-containing heterocyclyl, substituted N-containing heterocyclyl, NH-alkyl, NH-substituted alkyl and NH_2.

97. (Cancelled)

98. (Original) A compound of claim 1, wherein

R_1 is hydrogen;

R_2 is  ;

R_3 is –ORm;

R_5 is hydrogen;

R_6 is hydrogen; and

m is 0.

99. (Original) The compound of claim 98, wherein

R_4 is carboxyl, C_{1-4} alkyl ester, hydroxyl methyl, CH_2OCH_2-C_6H_5, or CH_2OCH_3.

100. (Original) The compound of claim 98, where Rm is hydrogen or C_1-C_5 alkyl.

101. (Original) The compound of claim 98, herein W is H, OH, NHCO-$(CH_2)_{0-3}$-aryl, NHCO-$(CH_2)_{0-3}$-substituted aryl, NHCO-$(CH_2)_{0-3}$-heteroaryl, NHCO-$(CH_2)_{0-3}$-substituted aryl, OCO-$(CH_2)_{0-3}$-aryl, OCO-$(CH_2)_{0-3}$-substituted aryl, OCO-$(CH_2)_{0-3}$-heterosryl, OCO-$(CH_2)_{0-3}$-substituted aryl, O-$(CH_2)_{0-3}$-heterocyclyl, -O-$(CH_2)_{0-3}$-substituted heterocyclyl, NHCO-$(CH_2)_{0-3}$-heterocyclyl, NHCO-$(CH_2)_{0-3}$-substituted heterocyclyl, O-$(CH_2)_{0-3}$-alkynyl, O-$(CH_2)_{0-3}$-alkenyl, or halogen.

102. (Original) A compound of claim 1, wherein

R_1 is hydrogen or C_{1-5} alkyl;

R_2 is OH, or NH_2;

R_5 is hydrogen;

R_6 is hydrogen; and

m is 0.

103. (Original) The compound of claim 102, wherein

R_4 is CONH-aryl, CONH-substituted aryl, or $(CH_2)_{1-3}$-O-CH_3.